Cargando…
Correlation between Acinetobacter baumannii Resistance and Hospital Use of Meropenem, Cefepime, and Ciprofloxacin: Time Series Analysis and Dynamic Regression Models
Acinetobacter baumannii is one of the most difficult-to-treat pathogens worldwide, due to developed resistance. The aim of this study was to evaluate the use of widely prescribed antimicrobials and the respective resistance rates of A. baumannii, and to explore the relationship between antimicrobial...
Autores principales: | Kousovista, Rania, Athanasiou, Christos, Liaskonis, Konstantinos, Ivopoulou, Olga, Ismailos, George, Karalis, Vangelis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071258/ https://www.ncbi.nlm.nih.gov/pubmed/33920945 http://dx.doi.org/10.3390/pathogens10040480 |
Ejemplares similares
-
The Role of Uniform Meropenem Usage in Acinetobacter baumannii Clone Replacement
por: Balázs, Bence, et al.
Publicado: (2021) -
Evaluation of synergistic effect of tazobactam with meropenem and ciprofloxacin against multi-drug resistant Acinetobacter baumannii isolated from burn patients in Tehran
por: Valadan Tahbaz, Sahel, et al.
Publicado: (2019) -
Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations
por: Karalis, Vangelis, et al.
Publicado: (2020) -
Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021) -
Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
por: Dahdouh, E., et al.
Publicado: (2014)